Profile data is unavailable for this security.
About the company
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
- Revenue in USD (TTM)0.00
- Net income in USD-37.18m
- Incorporated2013
- Employees18.00
- LocationBioVie Inc680 W NYE LANE, SUITE 201CARSON CITY 89703United StatesUSA
- Phone+1 (775) 888-3162
- Websitehttps://www.bioviepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aprea Therapeutics Inc | 963.81k | -12.72m | 25.90m | 7.00 | -- | 0.8955 | -- | 26.87 | -3.32 | -3.32 | 0.2503 | 5.57 | 0.0296 | -- | -- | 137,687.10 | -39.00 | -68.66 | -43.83 | -77.19 | -- | -- | -1,319.45 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Unity Biotechnology Inc | 0.00 | -34.78m | 26.02m | 19.00 | -- | 1.08 | -- | -- | -2.33 | -2.33 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -40.18 | -47.21 | -48.47 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Singular Genomics Systems Inc | 2.49m | -96.21m | 27.02m | 255.00 | -- | 0.1724 | -- | 10.85 | -1.31 | -1.31 | 0.034 | 2.12 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 27.17m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 27.25m | 3.00 | -- | 1.04 | -- | 63.16 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Oncternal Therapeutics Inc | 1.15m | -36.38m | 27.26m | 27.00 | -- | 1.19 | -- | 23.68 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -47.99m | 27.49m | 40.00 | -- | 4.88 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -8.05m | 27.78m | 8.00 | -- | 11.07 | -- | -- | -0.7249 | -0.7249 | 0.00 | 0.1048 | 0.00 | -- | -- | 0.00 | -172.23 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| BioVie Inc | 0.00 | -37.18m | 27.79m | 18.00 | -- | 1.47 | -- | -- | -0.9626 | -0.9626 | 0.00 | 0.3104 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
| Biomx Inc | 0.00 | -37.14m | 27.92m | 58.00 | -- | -- | -- | -- | -0.6234 | -0.6234 | 0.00 | 0.3813 | 0.00 | -- | -- | 0.00 | -60.38 | -- | -72.74 | -- | -- | -- | -- | -- | -- | -2.25 | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
| bioAffinity Technologies Inc | 4.94m | -8.37m | 27.98m | 75.00 | -- | 5.12 | -- | 5.67 | -0.9197 | -0.9197 | 0.5416 | 0.4687 | 0.5334 | 318.22 | 8.70 | 65,839.60 | -90.38 | -- | -104.93 | -- | 32.88 | -- | -169.42 | -- | 2.21 | -- | 0.1782 | -- | 52,660.42 | -- | 2.66 | -- | -- | -- |
| NanoViricides Inc | 0.00 | -9.51m | 28.35m | 7.00 | -- | 2.66 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 28.60m | 298.00 | -- | 0.6684 | -- | 0.6154 | -0.2176 | -0.2176 | 1.30 | 1.20 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Bolt Biotherapeutics Inc | 11.32m | -63.03m | 28.85m | 100.00 | -- | 0.277 | -- | 2.55 | -1.66 | -1.66 | 0.2987 | 2.73 | 0.0649 | -- | -- | 113,240.00 | -36.11 | -48.32 | -39.88 | -54.03 | -- | -- | -556.59 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 29.05m | 34.00 | -- | 18.40 | -- | 4.92 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
Data as of May 31 2024. Currency figures normalised to BioVie Inc's reporting currency: US Dollar USD
11.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Altium Capital Management LPas of 31 Mar 2024 | 3.01m | 5.49% |
| Sabby Management LLCas of 31 Mar 2024 | 689.14k | 1.26% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 619.11k | 1.13% |
| Heights Capital Management, Inc.as of 31 Mar 2024 | 599.90k | 1.09% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 347.40k | 0.63% |
| swisspartners AGas of 30 Jun 2023 | 300.00k | 0.55% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 286.71k | 0.52% |
| Geode Capital Management LLCas of 31 Mar 2024 | 247.11k | 0.45% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 175.17k | 0.32% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 103.35k | 0.19% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
